Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression

Cheng-Ta Li, MD, PhD, has devoted his career to a deceptively simple question: why do patients with apparently similar depression follow such different paths, and can psychiatry learn to tell them apart before treatment begins? A psychiatrist and neuroscientist, he is Professor at the School of Medicine and Institute of Brain Science of National Yang Ming Chiao Tung University and directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital. Opened in June 2022 as Taiwan's first center devoted to precision care for depression, PreDIC concentrates on treatment-resistant depression (TRD) and has since recorded more than 20,000 patient visits. Its guiding idea is that treatment resistance is not a yes-or-no verdict but a continuum, one that can be staged by severity and degree of refractoriness. To give that idea clinical form, Dr. Li and his team built AI-PreDIC®, a patented platform that reads clinical data alongside EEG and FDG-PET to estimate where each patient stands, an early step toward bringing TRD staging into routine practice. The center rests on a long record of research. His 2014 randomized sham-controlled trial in Brain was among the first large trials of theta-burst stimulation for refractory depression, and his group went on to help establish theta-burst stimulation, repetitive transcranial magnetic stimulation, and low-dose ketamine and esketamine in Taiwanese psychiatry. His population studies have shown, among other findings, that TRD runs strongly in families. Today his attention turns to the brain networks through which specific treatments act, to TMS-EEG measures of cortical excitation and inhibition, to imaging biomarkers and machine learning that might match patients to therapies, and to emerging treatments such as psychedelics. The author of more than 300 peer-reviewed publications, he has carried this science into patents, technology transfer, clinical consensus, and professional training. He is also founding President of the Taiwanese Society of Brain Stimulation and has served as Secretary General of the Asian College of Neuropsychopharmacology. In this Genomic Press Interview, he reflects on the patients and the early skepticism that drew him to brain stimulation, the mentors who shaped his scientific values, and his hope of moving depression care from trial and error toward precision.

Authors

Institutions

Publication Details

Journal
Brain medicine :
Published
2026-11-17
DOI
https://doi.org/10.61373/bm026k.0069
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression

Cheng‐Ta Li
1 links
Brain medicine :
Treatment of Major Depression
article

Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression

Cheng‐Ta Li
article en

Abstract

Cheng-Ta Li, MD, PhD, has devoted his career to a deceptively simple question: why do patients with apparently similar depression follow such different paths, and can psychiatry learn to tell them apart before treatment begins? A psychiatrist and neuroscientist, he is Professor at the School of Medicine and Institute of Brain Science of National Yang Ming Chiao Tung University and directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital. Opened in June 2022 as Taiwan's first center devoted to precision care for depression, PreDIC concentrates on treatment-resistant depression (TRD) and has since recorded more than 20,000 patient visits. Its guiding idea is that treatment resistance is not a yes-or-no verdict but a continuum, one that can be staged by severity and degree of refractoriness. To give that idea clinical form, Dr. Li and his team built AI-PreDIC®, a patented platform that reads clinical data alongside EEG and FDG-PET to estimate where each patient stands, an early step toward bringing TRD staging into routine practice. The center rests on a long record of research. His 2014 randomized sham-controlled trial in Brain was among the first large trials of theta-burst stimulation for refractory depression, and his group went on to help establish theta-burst stimulation, repetitive transcranial magnetic stimulation, and low-dose ketamine and esketamine in Taiwanese psychiatry. His population studies have shown, among other findings, that TRD runs strongly in families. Today his attention turns to the brain networks through which specific treatments act, to TMS-EEG measures of cortical excitation and inhibition, to imaging biomarkers and machine learning that might match patients to therapies, and to emerging treatments such as psychedelics. The author of more than 300 peer-reviewed publications, he has carried this science into patents, technology transfer, clinical consensus, and professional training. He is also founding President of the Taiwanese Society of Brain Stimulation and has served as Secretary General of the Asian College of Neuropsychopharmacology. In this Genomic Press Interview, he reflects on the patients and the early skepticism that drew him to brain stimulation, the mentors who shaped his scientific values, and his hope of moving depression care from trial and error toward precision.

Brain medicine :
National Yang Ming Chiao Tung University (TW), Taipei Veterans General Hospital (TW)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon